ESALF News and Press, Eisai Co Ltd From 09/28/21

With a list of 62 recent IPOs making entry to The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 recalibrations, we discuss the recently-IPOd healthcare stocks joining the index. Following up on our previous article on biotech stocks in the group, ...

Eisai is close to delivering treatment to slow the progress of Alzheimer's disease, but on closer inspection, we do not think Aduhelm is the answer. Shorter-term earnings visibility may suffer as a result. Earnings outlook longer-term from lecanemab is promising, but any positive impa...

With Labor Day marking the unofficial end of summer, September looks to be a busy month for events impacting pharmaceutical and biotechnology  companies. Here's a look at what events to look forward to this month that could impact pharma and biotech stocks. Sept. 3: FDA Cellular, Tissue,...

Eisai Co., Ltd. (ESALF) Q1 2022 Earnings Conference Call August 04, 2021 03:00 AM ET Company Participants Ryohei Yanagi - Executive Vice President & Chief Financial Officer Ivan Cheung - Senior Vice President & President of Neurology Business Group Terushige Iike - Senior Vice Preside...

Eisai (OTCPK:ESALY -1.4%) will "seek the most optimal and expedited regulatory pathway forward for lecanemab," an Alzheimer's candidate under development with Biogen (BIIB -0.2%), according to Ivan Cheung, Eisai's (OTCPK:ESALF) head of neurology. Cheung made the comments today during the comp...

knowlesgallery/iStock via Getty Images The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online. As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to...

Merck (MRK) announces that the FDA has approved the combination of Keytruda, plus Eisai's (ESALF) Lenvima for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression fol...

kunertus/iStock via Getty Images The FDA and Alzheimer's drug developers are looking at ways to potentially speed up post-marketing confirmatory trials, according to a discussion guide of a meeting held yesterday by the Duke Margolis Center for Public Health. As a condition of the approval of...

With XPro1595, it has a disease-modifying drug candidate that has already shown to consistently decrease multiple biomarkers of neuroinflammation; The test is now how this affects biomarkers of neurodegeneration and AD; readout to be expected in August 2021; INmune Bio is not an A...

drnadig/iStock via Getty Images U.S. lawmakers investigating the controversial FDA approval granted for Alzheimer’s therapy Aduhelm (aducanumab) have asked Biogen (BIIB) to submit years of internal documents related to the drug’s development and the company’s interactions...